{"id":"W2606334551","doi":"10.1002/cpdd.358","title":"Single‐ and Multiple‐Dose Pharmacokinetics of Once‐Daily Formulations of Raltegravir","year":2017,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"ca_institutions":"Pharma Medica Research (Canada)","funders":"Merck","keywords":"Raltegravir; Pharmacokinetics; Bioavailability; Pharmacology; Medicine; Biopharmaceutics; Dosing; Biopharmaceutics Classification System; In vivo; Human immunodeficiency virus (HIV); Chemistry; Virology; Antiretroviral therapy; In vitro; Biological activity; Biology; Viral load; Biochemistry; Pharmacognosy; Biotechnology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008348278,0.0002464436,0.0008052657,0.0002030034,0.000147403,0.000009388248,0.0002451532,0.0001471919,0.0001379385],"category_scores_gemma":[0.0003655844,0.0002124006,0.0001159938,0.0001056676,0.000590464,0.000101134,0.0002585744,0.0003261893,0.00001828972],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001033578,"about_ca_system_score_gemma":0.0004081024,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001547628,"about_ca_topic_score_gemma":0.00004154088,"domain_scores_codex":[0.9974546,0.0001094915,0.001458022,0.0003958525,0.0002521917,0.0003298877],"domain_scores_gemma":[0.9980251,0.0006594227,0.0005999003,0.0003062768,0.0001779999,0.0002313529],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001021389,0.003355348,0.9116704,0.0002224362,0.0006664721,0.0001249954,0.002315409,0.00001118167,0.01380762,0.00007068578,0.00622914,0.06050496],"study_design_scores_gemma":[0.01976175,0.0001648246,0.8449247,0.0002302719,0.0003327226,0.00001313244,0.0001168135,0.0006442402,0.1053385,0.0001299676,0.0280559,0.0002871191],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9934002,0.0002124469,0.00002442036,0.00278382,0.0006740497,0.0007805535,0.000009397805,0.00002200989,0.002093113],"genre_scores_gemma":[0.9805075,0.0004677389,0.01590535,0.0002694845,0.0001005241,0.00003786967,0.00003081134,0.0000218771,0.002658838],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.09153087,"threshold_uncertainty_score":0.8661444,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08495309511939617,"score_gpt":0.4174303690147653,"score_spread":0.3324772738953691,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}